1Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry, 1988, 4;5 : 1094-1099.
2Bucci P, Mucci A, Volpe U, et al. Executive hypercontrol in obsessive-compulsive disorder : clectrophysiological and neuropsychological indices. Clin Neurophysiol, 2004, 115 : 1340-1348.
3Riffkin J, Yucel M, Maruff P, et al. A manual and automated MRI study of anterior cingulate and orbito-frontal cortices, and caudate nucleus in obsessive-compulsive disorder: comparison with healthy controls and patients with schizophrenia. Psychiatry Res, 2005,138:99-113.
4Ho Pian KL, van Megen HJ, Ramsey NF, et al. Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res, 2005, 138:89-97.
5Dougherty DD, Baer L, Cosgrove GR, et al. Prospective long-term follow-up of 44 patients who received cingulotomy for treatmentrefractory obsessive-compulsive disorder. Am J Psychiatry, 2002,159:269-275.
6Baumgarten HG, Grozdanovic Z. Role of serotonin in obsessivecompulsive disorder. Br J Psychiatry Suppl, 1998, (35) : 13-20.
2Sham P, Curtis D. An extended transmission/disequilibrium test (TDT) for multiallele marker loci. Ann Hum Genet,1995,59:323-336.
3McDougle CJ, Epperson CN, Price LH, et al. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive-compulsive disorder. Mol Psychiatry,1998,3:270-273.
4Bengel D, Greenberg BD, Cora-Locatelli G, et al. Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder. Mol Psychiatry,1999,4:463-466.
5Di Bella D, Erzegovesi S, Cavallini MC, et al. Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J,2002,2:176-181.
7Spurlock G, Heils A,Holmans P, et al. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry,1998,3:42-49.
8Collier DA, Stober G, Li T, et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry, 1996,1:453-460.
9Arinami T, Gao M , Hamaguchi H, et al. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet,1997,6:577-582.
10Okuyama Y, Ishiguro H, Nankai M, et al. Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. Mol Psychiatry, 2000, 5:64-69.
5Stein DJ, Montgomery SA. Kasper S. Predicctors of respons to pharmacotherrapy with eitalopran in obsessine compulsive disord. International Clinical psychopharmacology ,2001,16 (6) :357.
6汪向东 王希林 等.心理卫生评定量表[M].北京:中国心理卫生杂志社,1999.306-310.
7沈渔村．精神病学．4版．北京：人民卫生出版社，2001．
8Yaryura-Tobias JA, Neziroglu FM, Kaplan S. Self-mutila- tion, anorexia, and dysmenorrhea in obsessive compulsive disorder. Int J Eat Disord, 1995, 17(1): 33-38.
9Stein DJ, Ipser JC, Baldwin DS, Bandelow B. Treatment of obsessive-compulsive disorder. CNS Spectrum, 2007,12(2): 28-35.
10Yilmaz N, Genctiz TAKM. Psychometric properties of the defense style questionnaire: A reliability and validity study. Turkish Journal of Psychiatry, 2007, 18(3): 244-253.
